Source: International Congress 2014 – Pulmonary hypertension: clinical management
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Chakinala, R. Frantz, R. Schilz, W. Benton, D. Miller, B. Hartline, C. L. Vampola, D. Rosenberg, H. Farber (St. Louis, Rochester, Cleveland, South San Francisco, San Francisco, Boston, United States Of America; Allschwil, Switzerland). Epoprostenol dosing by concomitant therapies in the PROSPECT registry. Eur Respir J 2014; 44: Suppl. 58, 2373

Member's Comments

No comment yet.

Related content which might interest you: Long-term data from the Swiss pulmonary hypertension registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Nebivolol and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Pulmonary arterial hypertension – A single-centre experience Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Prognosis factors of recurrent pulmonary thromboembolism Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Immune signatures in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Improving the safety of right heart catheterisation in sickle cell disease Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 An overview of thrombolytic treatment for pulmonary embolism: A single center experience Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Characteristics of patients with pulmonary hypertension in end stage renal disease Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Endothelial-to-mesenchymal transition in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Long-term screening for pulmonary hypertension after pulmonary embolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Rivaroxaban for treatment of venous thromboembolism. A real-life perspective in 103 patients Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Non-invasive cardiac output assessment in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Portopulmonary hypertension in United Kingdom: A contemporary, national, observational study Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Molecular study of genetic modifiers in patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014